OLIVER W PRESS
Osteopathic Medicine at Eastlake Ave, Seattle, WA
License number
Washington MD00020170
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
825 Eastlake Ave EAST, Seattle, WA 98109
Phone
(206) 288-1000
(206) 543-6420
(206) 543-6420
Personal information
See more information about OLIVER W PRESS at radaris.comName
Address
Phone
11018 Exeter Ave NE, Seattle, WA 98125
Seattle, WA
11018 Exeter Ave NE, Seattle, WA 98125
Organization information
See more information about OLIVER W PRESS at bizstanding.comOliver W Press MD
1100 Fairview Ave N #D3-100, Seattle, WA 98109
Categories:
Oncology Physicians & Surgeons
Phone:
(206) 667-5000 (Phone)
Oliver W Press MD
825 Eastlake Ave E, Seattle, WA 98109
Categories:
Hematology Physicians & Surgeons
Oliver W. Press LLC
11018 Exeter Ave NE, Seattle, WA 98125
Status:
Inactive
Registration:
May 22, 2006
State ID:
200615610039
Business type:
Foreign
Entity State:
CA
Agent:
Lloyd Lowrey
Professional information
Dr. Oliver W Press, Seattle WA - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
Fred Hutchinson Cncr Rsrch Ctr
1100 Fairview Ave N SUITE D3-100, Seattle 98109
(206) 667-5000 (Phone)
Seattle Cancer Care Alliance
825 Eastlake Ave E, Seattle 98109
(855) 557-0555 (Phone)
1100 Fairview Ave N SUITE D3-100, Seattle 98109
(206) 667-5000 (Phone)
Seattle Cancer Care Alliance
825 Eastlake Ave E, Seattle 98109
(855) 557-0555 (Phone)
Certifications:
Internal Medicine, 1982, Medical Oncology, 1985
Awards:
Healthgrades Honor Roll
Languages:
English, German
Hospitals:
Fred Hutchinson Cncr Rsrch Ctr
1100 Fairview Ave N SUITE D3-100, Seattle 98109
Seattle Cancer Care Alliance
825 Eastlake Ave E, Seattle 98109
Harborview Medical Center
325 9Th Ave, Seattle 98104
University of Washington Medical Center
1959 East Pacific St, Seattle 98195
1100 Fairview Ave N SUITE D3-100, Seattle 98109
Seattle Cancer Care Alliance
825 Eastlake Ave E, Seattle 98109
Harborview Medical Center
325 9Th Ave, Seattle 98104
University of Washington Medical Center
1959 East Pacific St, Seattle 98195
Education:
Medical School
University of Washington
Graduated: 1979
Massachusetts General Hospital
U Hosp
University Of Washington
University of Washington
Graduated: 1979
Massachusetts General Hospital
U Hosp
University Of Washington
Oliver W Press, Seattle WA
Specialties:
Oncologist
Address:
825 Eastlake Ave E, Seattle, WA 98109
Education:
University of Washington, School of Medicine - Doctor of Medicine
University of Washington - Doctor of Philosophy
University of Washington Medical Center - Fellowship - Oncology (Internal Medicine)
University of Washington Medical Center - Residency - Internal Medicine
Massachusetts General Hospital - Residency - Internal Medicine
University of Washington - Doctor of Philosophy
University of Washington Medical Center - Fellowship - Oncology (Internal Medicine)
University of Washington Medical Center - Residency - Internal Medicine
Massachusetts General Hospital - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Oliver William Press, Seattle WA
Specialties:
Internal Medicine, Medical Oncology, Hematology & Oncology, Hematology
Work:
Seattle Cancer Care Alliance
825 Eastlake Ave E, Seattle, WA 98109 Seattle Cancer Care Alliance - Inpatient at Uwmc
1959 Ne Pacific St, Seattle, WA 98195
825 Eastlake Ave E, Seattle, WA 98109 Seattle Cancer Care Alliance - Inpatient at Uwmc
1959 Ne Pacific St, Seattle, WA 98195
Education:
University of Washington (1979)
Member At Fred Hutchinson Cancer Research Center
Position:
Member at Fred Hutchinson Cancer Research Center
Location:
Greater Seattle Area
Industry:
Hospital & Health Care
Work:
Fred Hutchinson Cancer Research Center
-
Member
Enhanced Transport Using Membrane Disruptive Agents
US Patent:
7374778, May 20, 2008
Filed:
May 28, 2004
Appl. No.:
10/857626
Inventors:
Allan S. Hoffman - Seattle WA, US
Patrick Stayton - Seattle WA, US
Oliver W. Press - Seattle WA, US
Niren Murthy - Atlanta GA, US
Chantal Lackey Reed - Del Mar CA, US
Lawrence A. Crum - Bellevue WA, US
Pierre D. Mourad - Seattle WA, US
Tyrone M. Porter - Boston MA, US
David Tirrell - Pasadena CA, US
Patrick Stayton - Seattle WA, US
Oliver W. Press - Seattle WA, US
Niren Murthy - Atlanta GA, US
Chantal Lackey Reed - Del Mar CA, US
Lawrence A. Crum - Bellevue WA, US
Pierre D. Mourad - Seattle WA, US
Tyrone M. Porter - Boston MA, US
David Tirrell - Pasadena CA, US
Assignee:
University of Washington - Seattle WA
University of Massachusetts - Boston MA
University of Massachusetts - Boston MA
International Classification:
A61K 9/127, A61K 9/14, A61K 9/16, A61K 47/00
US Classification:
424450, 424489, 424501, 424 7809, 5147726
Abstract:
Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes, coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered.
Enhanced Transport Using Membrane Disruptive Agents
US Patent:
8003129, Aug 23, 2011
Filed:
Apr 18, 2008
Appl. No.:
12/105983
Inventors:
Allan S. Hoffman - Seattle WA, US
Patrick Stayton - Seattle WA, US
Oliver W. Press - Seattle WA, US
Niren Murthy - Atlanta GA, US
Chantal Lackey Reed - Del Mar CA, US
Lawrence A. Crum - Bellevue WA, US
Pierre D. Mourad - Seattle WA, US
Tyrone M. Porter - Boston MA, US
David Tirrell - Pasadena CA, US
Patrick Stayton - Seattle WA, US
Oliver W. Press - Seattle WA, US
Niren Murthy - Atlanta GA, US
Chantal Lackey Reed - Del Mar CA, US
Lawrence A. Crum - Bellevue WA, US
Pierre D. Mourad - Seattle WA, US
Tyrone M. Porter - Boston MA, US
David Tirrell - Pasadena CA, US
Assignee:
University of Washington - Seattle WA
Univeristy of Massachusetts - Boston MA
Univeristy of Massachusetts - Boston MA
International Classification:
A61K 9/14, A61K 9/16, A61K 47/00, A61K 9/127
US Classification:
424501, 424489, 424450, 5147726
Abstract:
Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes, coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered.
Enhanced Transport Using Membrane Disruptive Agents
US Patent:
2001000, Jul 12, 2001
Filed:
Jan 5, 1999
Appl. No.:
09/226044
Inventors:
ALLAN S. HOFFMAN - SEATTLE WA, US
PATRICK STAYTON - SEATTLE WA, US
OLIVER W. PRESS - SEATTLE WA, US
DAVID TIRRELL - PASADENA CA, US
NIREN MURTHY - SEATTLE WA, US
CHANTAL LACKEY - SEATTLE WA, US
LAWRENCE A. CRUM - ISSAQUAH WA, US
PIERRE D. MOURAD - SEATTLE WA, US
TYRONE M. PORTER - SEATTLE WA, US
PATRICK STAYTON - SEATTLE WA, US
OLIVER W. PRESS - SEATTLE WA, US
DAVID TIRRELL - PASADENA CA, US
NIREN MURTHY - SEATTLE WA, US
CHANTAL LACKEY - SEATTLE WA, US
LAWRENCE A. CRUM - ISSAQUAH WA, US
PIERRE D. MOURAD - SEATTLE WA, US
TYRONE M. PORTER - SEATTLE WA, US
International Classification:
A61K009/00
US Classification:
424/400000
Abstract:
Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes, coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and/or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontopheresis, and/or electrophereis can also be used with the disrupting agents.
Enhanced Transport Using Membrane Disruptive Agents
US Patent:
2011028, Nov 24, 2011
Filed:
Jul 14, 2011
Appl. No.:
13/182756
Inventors:
Allan S. Hoffman - Seattle WA, US
Patrick Stayton - Seattle WA, US
Oliver W. Press - Seattle WA, US
Niren Murthy - Atlanta GA, US
Chantal Lackey Reed - Del Mar CA, US
Lawrence A. Crum - Bellevue WA, US
Pierre D. Mourad - Seattle WA, US
Tyrone M. Porter - Boston MA, US
David Tirrell - Pasadena CA, US
Patrick Stayton - Seattle WA, US
Oliver W. Press - Seattle WA, US
Niren Murthy - Atlanta GA, US
Chantal Lackey Reed - Del Mar CA, US
Lawrence A. Crum - Bellevue WA, US
Pierre D. Mourad - Seattle WA, US
Tyrone M. Porter - Boston MA, US
David Tirrell - Pasadena CA, US
Assignee:
UNIVERSITY OF MASSACHUSETTS - Boston MA
UNIVERSITY OF WASHINGTON - Seattle WA
UNIVERSITY OF WASHINGTON - Seattle WA
International Classification:
C08F 220/06, C08F 265/02, C08F 299/00
US Classification:
525299, 525301, 5253297
Abstract:
Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes, coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and/or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontopheresis, and/or electrophoresis can also be used with the disrupting agents.
Pre-Targeted Nanoparticle System And Method For Labeling Biological Particles
US Patent:
2013030, Nov 21, 2013
Filed:
Apr 29, 2013
Appl. No.:
13/872827
Inventors:
Oliver W. Press - Seattle WA, US
Jonathan Whitney Gunn - Seattle WA, US
Steven I. Park - Mountlake Terrace WA, US
Jonathan Whitney Gunn - Seattle WA, US
Steven I. Park - Mountlake Terrace WA, US
Assignee:
University of Washington through its Center for Commercialization - Seattle WA
International Classification:
A61K 47/48, A61K 48/00, A61K 49/00
US Classification:
424 91, 4241781, 435 71
Abstract:
Nanoparticle system and method for labeling, detecting, and treating biological particles. In the method, targeting functionality (fusion protein) and therapeutic/imaging modalities (nanoparticle) are separated.